The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 Study.

Date publication

février 2023

Journal

European urology oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CORMIER Luc , Pr PEIFFERT Didier , Dr QUIVRIN Magali

Tous les auteurs :
Pasquier D, Lacornerie T, Supiot S, Pommier P, Quivrin M, Simon JM, Loos G, Meyer E, Calais G, Peiffert D, Vandendorpe B, Aymes E, Leguillette C, Brihoum M, Nenan S, Cormier L, Le Deley MC, Lartigau EF

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36754722

Résumé

There is no consensus on the best local salvage treatment for prostate cancer recurrence after primary external beam radiotherapy. Prospective data on stereotactic body radiation therapy (SBRT) are very scarce.

Mots clés

Local recurrence, Phase 1, Prostate cancer, Radiation therapy, Reirradiation, Salvage stereotactic body radiation therapy, Stereotactic body radiation therapy

Référence

Eur Urol Oncol. 2023 02 6;: